Literature DB >> 17720322

Challenges and prospects of immunotherapy as cancer treatment.

Maria Rescigno1, Francesca Avogadri, Giuseppe Curigliano.   

Abstract

The concept of cancer immunotherapy stems from the proposed function of the immune system, called immunosurveillance, to protect against growing tumors. Due to genetic aberrations, tumor cells display an altered repertoire of MHC-associated peptides that can lead to the activation of immune cells able to eliminate the transformed cells. In some instances, under the pressure of the immune system, both the tumor and its microenvironment are shaped and immune-resistant tumor variants are selected initiating the process of cancer immunoediting. This can impair not only host-generated immunosurveillance, but also attempts to harness the immune response for therapeutic purposes, namely immunotherapy. Rather than being an exhaustive review of the different approaches of cancer immunotherapy, the focus of this review is to provide the reader with future challenges of the field by proposing 'second generation' immunotherapy approaches that take into account immunosubversive mechanisms adopted by tumor cells. After an introduction on the process of immunosurveillance and immunoescape we will analyze why current immunotherapy approaches have not fulfilled their promise and will finish by summarizing what are the challenges for future approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720322     DOI: 10.1016/j.bbcan.2007.07.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

Review 1.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

2.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 3.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

4.  FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Authors:  Amy K Erbe; Wei Wang; Jacob Goldberg; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; James W Mier; David J Panka; David F McDermott; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2016-10-14       Impact factor: 12.531

5.  Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.

Authors:  Jun Wang; Zhi Peng Gao; Song Qin; Chang Bai Liu; Li Li Zou
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

6.  Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.

Authors:  Serena Pellegatta; Pietro Luigi Poliani; Elena Stucchi; Daniela Corno; Chiara Agnese Colombo; Francesca Orzan; Maria Ravanini; Gaetano Finocchiaro
Journal:  Neuro Oncol       Date:  2010-01-06       Impact factor: 12.300

7.  Tumor vaccines in renal cell carcinoma.

Authors:  Hirotsugu Uemura; Marco A De Velasco
Journal:  World J Urol       Date:  2008-03-12       Impact factor: 4.226

8.  Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.

Authors:  Brian T Weinert; Kausilia K Krishnadath; Francesca Milano; Ayako W Pedersen; Mogens H Claesson; Mai-Britt Zocca
Journal:  Cancer Immun       Date:  2009-10-09

9.  N-Propionyl polysialic acid precursor enhances the susceptibility of multiple myeloma to antitumor effect of anti-NprPSA monoclonal antibody.

Authors:  Hong Xiong; Ai-bin Liang; Bing Xiu; Jian-Fei Fu; Yi Ding; Yu-hua Chen
Journal:  Acta Pharmacol Sin       Date:  2012-11-05       Impact factor: 6.150

Review 10.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.